Post

More from @Abdallah81MD

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Jul 3

🧵1/🌍🔬
Our new USMIRC analysis evaluated 845 multiple myeloma clinical trials registered on over the past 20 years, examining where trials are conducted, how they have evolved, and who has access to innovation.

#mmsm #myeloma #MedEd #medtwitter #USMIRC @US_HMC @USMIRCNEWS @Larvol @MedwatchKate @oncodaily @CurrentOncologyClinicalTrials.gov

2/ 🌍 The Global Myeloma Trial Boom—But Not Everyone Is Benefiting

MM clinical research has expanded dramatically worldwide, reflecting the rapid evolution of immunotherapy, CAR-T, bispecific antibodies, and targeted therapies. Yet this growth has not been equally distributed.

The United States 🇺🇸🏆 remains the global leader, accounting for nearly 40% of all MM trials, with the highest trial density and the largest concentration of clinical trial sites.

#mmsm #myeloma #MedEd #medtwitter #USMIRC @US_HMC @USMIRCNEWS @Larvol @MedwatchKate @oncodaily

3/🤝🌎 Phase III Goes Global:

International collaboration has increased substantially, especially for Phase III studies, demonstrating that global partnerships are becoming the preferred model for large registration trials.

#mmsm #myeloma #MedEd #medtwitter #USMIRC @US_HMC @USMIRCNEWS @Larvol @MedwatchKate @oncodaily

Read 10 tweets

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Jun 14

🧵 Post-BCMA Failure in RRMM: What should we do next? 🤔

A new multicenter USMIRC/US academic center real-world analysis provides practical insights into sequencing after BCMA-directed therapy failure. Here are the key takeaways for clinicians 👇

1️⃣ BCMA-directed therapy failure is becoming increasingly common, yet the optimal sequencing strategy remains undefined.

📌 This analysis integrates 3 multicenter real-world cohorts evaluating:
🔹 BCMA CAR-T
🔹 BCMA bispecific antibodies
🔹 Talquetamab (GPRC5D)

#mmsm #myeloma #MedEd #Medtwitter #USMIRC @oncodaily @USMIRCNEWS @US_HMC @CurrentOncology @MedwatchKate @Larvol #المايلوما #سرطان_الدم

2️⃣ 🚀 BCMA CAR-T outperformed BCMA bispecifics after prior BCMA exposure.

✅ ORR: 79% vs 51%
✅ Median OS: 30 vs 12 months

👉 When feasible, CAR-T appears to provide the deepest and most durable responses.

#mmsm #myeloma #MedEd #Medtwitter #USMIRC @oncodaily @USMIRCNEWS @US_HMC @CurrentOncology @MedwatchKate @Larvol

3️⃣ 📉 Teclistamab after prior BCMA exposure demonstrated reduced efficacy.

Compared with BCMA-naïve patients:
🔸 ORR: 53% vs 68%
🔸 Median PFS: 2.5 vs 9.7 months

➡️ Prior BCMA exposure clearly impacts subsequent outcomes.

#mmsm #myeloma #MedEd #Medtwitter #USMIRC @oncodaily @USMIRCNEWS @US_HMC @CurrentOncology @MedwatchKate @Larvol #المايلوما #سرطان_الدم

Read 9 tweets

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Jun 13

🚨 MonumenTAL-3 (NEJM 2026): Talquetamab Beats the Old Standard of Care… But the Biggest Question Wasn’t Answered! 🧵

Can Talquetamab Truly Move Earlier—and Where Does It Fit After BCMA-Directed Therapy? Let’s Discuss the Ups, Downs & Future.

1/ Talquetamab continues to reshape the RRMM landscape.

The Phase III #MonumenTAL3 trial compared:
✅ Talquetamab + Daratumumab + Pomalidomide (Tal-DP)
✅ Talquetamab + Daratumumab (Tal-D)
vs
✅ DPd

Patients had ≥1 prior line of therapy.

#mmsm #myeloma #MedEd #Mestwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

2/ 🔥 Primary endpoint met

24-month PFS:
🟢 Tal-DP: 81.3%
🟢 Tal-D: 77.6%
⚪ DPd: 51.2%

HR:
📉 Tal-DP vs DPd = 0.28
📉 Tal-D vs DPd = 0.33

Highly significant improvement.

#mmsm #myeloma #MedEd #Mestwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

3/ 🎯 Depth of response

Overall Response Rate:
✅ Tal-DP 88.2%
✅ Tal-D 88.5%
⚪ DPd 77.6%

Complete Response:
✅ 71%
✅ 69%
⚪ 35%

MRD-negative CR:
✅ 52%
✅ 46%
⚪ 16%

Depth clearly favored GPRC5D-based therapy.

#mmsm #myeloma #MedEd #Mestwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

Read 11 tweets

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Jun 1

1/ 🧵 A Dominant Victory for BCMA: Teclistamab Scores Big in MajesTEC-9 from #ASCO26

Teclistamab moves earlier in RRMM!

MajesTEC-9 evaluated teclistamab monotherapy vs PVd/Kd in patients with MM after 1–3 prior lines, all exposed to lenalidomide + anti-CD38 mAb.

This is a very relevant post–Dara/Len era population. 👇

#mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily

2/ 🚀 Efficacy was impressive:

📌 18-mo PFS: 69.8% vs 26.9%
📌 HR for progression/death: 0.29
📌 CR or better: 65.9% vs 16.8%
📌 ORR: 84.5% vs 54.2%
📌 18-mo OS: 79.2% vs 68.6%
📌 OS HR: 0.60

A strong win for BCMA bispecific therapy earlier in relapse.

#mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily

3/ 🔬 Depth of response matters:

MRD-negative CR appeared much higher with teclistamab:
📌 ITT: 38.5% vs 6.7%

This suggests that moving T-cell–redirecting therapy earlier may capture better immune fitness and improve depth/durability of response.

#mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily

Read 11 tweets

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Apr 26

🧵🚨 Newly Diagnosed High-Risk Myeloma: Does “Double-Hit” Still Predict Worse Outcomes After ASCT?

1/In our multicenter real-world study of 154 transplant-eligible patients with high-risk MM, we compared:

🔹 Single-hit HRMM = 1 high-risk cytogenetic abnormality
🔹 Double-hit HRMM = ≥2 high-risk cytogenetic abnormalities

#MMSM #myeloma #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @OncoAlert @Larvol @USMIRCNEWS @CurrentOncology @KUcancercenter

2/📌 Cohort details:

👥 154 patients
🏥 3 U.S. academic centers
📅 Upfront ASCT between 2009–2024
🧬 63 single-hit
🧬 91 double-hit

High-risk lesions included del(17p), t(4;14), t(14;16), t(14;20), 1q gain/amp, and del(1p).

#MMSM #myeloma #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @OncoAlert @Larvol @USMIRCNEWS @CurrentOncology @KUcancercenter

3/🚨 Key finding:

Despite expectations, double-hit HRMM did not show significantly worse long-term survival compared with single-hit HRMM after frontline ASCT.

This challenges the idea that simply “counting hits” is enough in the modern treatment era.

#MMSM #myeloma #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @OncoAlert @Larvol @USMIRCNEWS @CurrentOncology @KUcancercenter

Read 10 tweets

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

Mar 13

🧵 High-Risk Myeloma Maintenance

1️⃣🧬 Maintenance Strategies in High-Risk Multiple Myeloma (HRMM)
New multicenter analysis from the USMIRC collaborative compares lenalidomide (R) vs bortezomib + lenalidomide (VR) maintenance after ASCT.

Key question:
👉 Does intensifying maintenance improve outcomes in HRMM?
#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @Larvol @US_HMC @MedwatchKate @OncoAlert

2️⃣ Background
📊 HRMM remains a major challenge despite modern induction + ASCT.

High-risk cytogenetics (per IMWG):
⚠️ del(17p)
⚠️ t(4;14)
⚠️ t(14;16) / t(14;20)
⚠️ +1q gain/amplification
⚠️ Double- or triple-hit disease

Standard maintenance = lenalidomide, but outcomes remain inferior in HRMM.

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @Larvol @US_HMC @MedwatchKate @OncoAlert

3️⃣ Study Design
🔬 USMIRC multicenter retrospective study

👥 97 HRMM patients
• R maintenance: 68
• VR maintenance: 29

Maintenance initiated within 180 days post-ASCT
📅 Study period: 2009–2024

Median age: ~60 yrs

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @Larvol @US_HMC @MedwatchKate @OncoAlert

Read 13 tweets

Share this page!

Enter URL or ID to Unroll

Al-Ola A Abdallah MD (USMIRC)

Try unrolling a thread yourself!

More from @Abdallah81MD

Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC)

Did Thread Reader help you today?

Don't want to be a Premium member but still want to support us?

Send Email!